NCT04449939 is a Phase 1 clinical trial of KY1005 in Immune System Diseases, sponsored by Kymab Limited.

Who is sponsoring NCT04449939?

NCT04449939 is sponsored by Kymab Limited.

What drugs are being tested in NCT04449939?

Interventions in NCT04449939: KY1005.

What condition does NCT04449939 study?

NCT04449939 studies Immune System Diseases.

Is NCT04449939 still recruiting?

NCT04449939 is currently completed. Last updated 30 September 2021.

Last reviewed 2021-09-30 · How we verify

NCT04449939

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Subcutaneous KY1005 in Healthy Volunteers

Completed Phase 1 Last updated 30 September 2021

What this trial tests

Phase 1 trial testing KY1005 in Immune System Diseases in 24 participants. Completed in 30 November 2020.

Timeline

7 July 2020

Primary endpoint
30 November 2020

30 November 2020

Quick facts

Lead sponsor	Kymab Limited
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	7 July 2020
Primary completion	30 November 2020
Estimated completion	30 November 2020
Sites	1 location across United Kingdom

Drugs / interventions tested

KY1005 — full drug profile →

Conditions studied

Immune System Diseases — all drugs for Immune System Diseases →

Sponsor

Kymab Limited — full company profile →

Who can join

Adults 18 to 45, male only, with Immune System Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Single centre, open-label, single dose, parallel group study to investigate the PK, safety and tolerability of KY1005 after subcutaneous (s.c.) and intravenous (i.v.) administration, with i.v. KY1005 as a reference treatment.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

TNF superfamily control of tissue remodeling and fibrosis.
Steele H, Cheng J, Willicut A, Dell G, et al · · 2023 · cited 50× · PMID 37465675 · DOI 10.3389/fimmu.2023.1219907
Tolerogenic Therapies in Cardiac Transplantation.
Wolner L, William-Olsson J, Podesser BK, Zuckermann A, et al · · 2025 · cited 1× · PMID 40362208 · DOI 10.3390/ijms26093968
Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis.
Tiraboschi G, Papp K, Bieber T, Weidinger S, et al · · 2025 · PMID 41035282 · DOI 10.1002/psp4.70121

Verify or expand the search:

Other trials of KY1005

Trials testing the same drug.

NCT03754309 — A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis · Phase 2 · completed
NCT03161288 — A Study of KY1005 in Healthy Volunteers · Phase 1 · completed

Other recruiting trials for Immune System Diseases

Currently open trials in the same condition.

NCT06575426 — A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes M · Phase 1, PHASE2 · recruiting
NCT06353087 — Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry) · recruiting
NCT06271252 — A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study · Phase 1 · recruiting
NCT06353035 — Biodiversity Interventions for Well-Being · NA · active not recruiting
NCT04656873 — Immuno-Oncology Database and Bioregistry · active not recruiting

Other Kymab Limited trials

Trials by the same sponsor.

NCT05131477 — Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study · Phase 2 · completed
NCT03829501 — A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Co · Phase 1, PHASE2 · terminated
NCT03754309 — A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis · Phase 2 · completed
NCT03161288 — A Study of KY1005 in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04449939 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kymab Limited
Last refreshed: 30 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04449939.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing